Maddi Hebebrand, MC, Associate Editor

Explore key insights and highlights from SPD 2025, focusing on pediatric dermatology advancements, innovative treatments, and expert reflections from the conference.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with the recent approval of delgocitinib for adults with moderate to severe CHE.

Explore the complexities of chronic hand eczema, its impact on quality of life, and emerging treatment options in this insightful review.

BioMendics initiates TAMES-02 trial for TolaSure, a groundbreaking therapy targeting the root cause of Epidermolysis Bullosa Simplex, offering new hope.

The drug’s approval in August 2025 follows robust efficacy and safety results from the DELTA 1, 2, and 3 clinical trials.

Patients receiving BoNT-A plus topical cream reported greater satisfaction and better skin lightness than with cream alone.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore the complexities of medication sampling, balancing patient access with ethical and safety concerns in clinical practice.

Parents advocate for children with chronic skin conditions, highlighting school challenges and the need for better support in pediatric dermatology.

Virginia Sybert, MD, emphasized the importance of using genetic testing judiciously in dermatologic care.

Temitayo Ogunleye, MD, guided clinicians through diverse AD cases to examine how newer agents fit into evolving treatment strategies.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Amlitelimab shows promise in enhancing clinical outcomes and patient quality of life in atopic dermatitis, offering potential for long-term disease control.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Kolansky identifies oxybenzone and fragrances as leading causes of sunscreen allergies.

The Japanese study found no association between cutaneous events and baseline EASI scores, eosinophil counts, or IgE levels.

Deucravacitinib-treated patients achieved superior clinical responses compared to placebo at week 16 in both trials.

The open-label trial showed dusquetide produced similar results to apremilast in reducing oral ulcers, pain, and ulcer duration.

At a recent Dermatology Times Case-Based Roundtable, attendees discussed several challenging AD cases.

Deepti Gupta, MD, emphasized SPD's focus on delivering practical clinical insights, highlighting emerging research, and fostering meaningful professional connections

VYNE Therapeutics reveals disappointing phase 2b trial results for repibresib gel in nonsegmental vitiligo, missing key efficacy endpoints.

Coates addresses social determinants of health in pediatric dermatology, emphasizing their impact on treatment and patient outcomes.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Johnson & Johnson seeks FDA approval to update guselkumab's label, highlighting its unique ability to significantly inhibit joint damage in active psoriatic arthritis.

The pediatric dermatology community mourns the loss of Dr Robert Sidbury, a beloved leader and mentor, celebrated for his compassion and groundbreaking contributions.

Catch up on coverage from the third day of the 50th Annual Society for Pediatric Dermatology Meeting in Seattle, Washington.

Eichenfield discussed the ever-evolving armamentarium, and how to navigate changes in the field.

Traditional mouse models for EBS are limited, prompting Simpson's lab to create more accurate human-based tissue models.